Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback